CG Oncology, Inc.
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -88.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -88.60% | |||
| Cost of Revenue | -91.62% | 2.49% | |||
| Gross Profit | 91.60% | -4.07% | |||
| SG&A Expenses | 17.72% | 26.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.35% | 9.74% | |||
| Operating Income | -15.49% | -10.92% | |||
| Income Before Tax | -20.24% | -8.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.24% | -8.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.24% | -8.35% | |||
| EBIT | -15.49% | -10.92% | |||
| EBITDA | -15.18% | -10.86% | |||
| EPS Basic | -20.19% | 1.80% | |||
| Normalized Basic EPS | -20.21% | 1.81% | |||
| EPS Diluted | -20.19% | 1.80% | |||
| Normalized Diluted EPS | -20.21% | 1.81% | |||
| Average Basic Shares Outstanding | 0.05% | 10.33% | |||
| Average Diluted Shares Outstanding | 0.05% | 10.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||